Frontage Holdings Corporation (HKG:1521)
1.080
0.00 (0.00%)
Feb 13, 2026, 3:11 PM HKT
Frontage Holdings Revenue
Frontage Holdings had revenue of $126.58M USD in the half year ending June 30, 2025, a decrease of -1.39%. This brings the company's revenue in the last twelve months to $253.01M, down -2.68% year-over-year. In the year 2024, Frontage Holdings had annual revenue of $254.91M, down -1.90%.
Revenue (ttm)
$253.01M
Revenue Growth
-2.68%
P/S Ratio
1.10
Revenue / Employee
$164.29K
Employees
1,540
Market Cap
2.19B HKD
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 254.91M | -4.95M | -1.90% |
| Dec 31, 2023 | 259.86M | 9.50M | 3.79% |
| Dec 31, 2022 | 250.36M | 65.92M | 35.74% |
| Dec 31, 2021 | 184.44M | 58.63M | 46.60% |
| Dec 31, 2020 | 125.81M | 25.40M | 25.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| Mabpharm | 464.53M |
| Cutia Therapeutics | 274.31M |
| Wuhan YZY Biopharma | 163.65M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 134.60M |
| Antengene Corporation | 92.43M |
| CANbridge Pharmaceuticals | 68.55M |
| Zhaoke Ophthalmology | 38.74M |